- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07069738
- Original retssag
Sikkerhed og effektivitet af venstre bundtgrenområde tempo versus konventionel hjerte -resynkroniseringsterapi i hjertesvigt (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jacqueline Beaulieu
- Telefonnummer: 1-800-227-3422
- E-mail: jacqueline.beaulieu@bsci.com
Studiesteder
-
-
Alabama
-
Huntsville, Alabama, Forenede Stater, 35801
- Rekruttering
- Heart Center Research, LLC
-
Kontakt:
- John Jennings, Dr.
-
Ledende efterforsker:
- John Jennings, Dr.
-
Mobile, Alabama, Forenede Stater, 36608
- Rekruttering
- Mobile Infirmary Medical Center
-
Kontakt:
- Ernest Matthew Quin, Dr.
-
Ledende efterforsker:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Rekruttering
- Mayo Clinic Phoenix
-
Kontakt:
- Mayank Sardana, MD
-
Ledende efterforsker:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, Forenede Stater, 72401
- Rekruttering
- Arrhythmia Research Group
-
Kontakt:
- Devi Nair, Dr.
-
Ledende efterforsker:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Scripps Memorial Hospital
-
Kontakt:
- Nicolas Olson, MD
-
Ledende efterforsker:
- Nicolas Olson, MD
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars Sinai Medical Center
-
Ledende efterforsker:
- Ashkan Ehdaie, MD
-
Kontakt:
- Ashkan Ehdaie, MD
-
Oakland, California, Forenede Stater, 94609
- Rekruttering
- Alta Bates Summit Medical Center
-
Kontakt:
- Rajan Shah, Dr.
-
Ledende efterforsker:
- Rajan Shah, Dr.
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- Pacific Heart Institute
-
Kontakt:
- Stephen Tang, MD
-
Ledende efterforsker:
- Stephan Tang, MD
-
Torrance, California, Forenede Stater, 90505
- Rekruttering
- Torrance Medical Center
-
Ledende efterforsker:
- Gene Kim, MD
-
Kontakt:
- Gene Kim, MD
-
Ventura, California, Forenede Stater, 93003
- Rekruttering
- Cardiology Associates Medical Group, Inc.
-
Kontakt:
- Jonathan Dukes, Dr.
-
Ledende efterforsker:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Washington Hospital Center
-
Kontakt:
- Cyrus Hadadi, MD
-
Ledende efterforsker:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, Forenede Stater, 34239
- Rekruttering
- Sarasota Memorial Hospital
-
Kontakt:
- Antonio Moretta, Dr.
-
Ledende efterforsker:
- Antonio Moretta, Dr.
-
Tampa, Florida, Forenede Stater, 33613
- Rekruttering
- AdventHealth Tampa
-
Ledende efterforsker:
- Kenneth Yamamura, MD
-
Kontakt:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30309
- Rekruttering
- Piedmont Hospital
-
Kontakt:
- Kavita Krishnasamy, MD
-
Ledende efterforsker:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital
-
Kontakt:
- Anand Shah, MD
-
Ledende efterforsker:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, Forenede Stater, 83642
- Rekruttering
- St. Luke's Idaho Cardiology Associates
-
Kontakt:
- Justice Oranefo, MD
-
Ledende efterforsker:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, Forenede Stater, 60521
- Rekruttering
- University of Chicago
-
Kontakt:
- Shrinath Yeshwant, MD
-
Ledende efterforsker:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, Forenede Stater, 60540
- Trukket tilbage
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46250
- Rekruttering
- Community Heart and Vascular Hospital
-
Kontakt:
- Krishna Malineni, MD
-
Ledende efterforsker:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa Hospitals and Clinics
-
Ledende efterforsker:
- Paari Dominic, MD
-
Kontakt:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40207
- Rekruttering
- Baptist Hospital East Louisville
-
Ledende efterforsker:
- Kevin Parrott, MD
-
Kontakt:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, Forenede Stater, 02720
- Rekruttering
- Southcoast Physicians Group
-
Kontakt:
- Arnoldas Giedrimas, MD
-
Ledende efterforsker:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan Hospitals
-
Ledende efterforsker:
- Thomas Crawford, MD
-
Kontakt:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, Forenede Stater, 49525
- Rekruttering
- Corewell Health
-
Kontakt:
- Jawad Wassim, MD
-
Ledende efterforsker:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, Forenede Stater, 55805
- Trukket tilbage
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, Forenede Stater, 56303
- Trukket tilbage
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, Forenede Stater, 07932
- Rekruttering
- Morristown Medical Center
-
Kontakt:
- Michael Katz, MD
-
Ledende efterforsker:
- Michael Katz, MD
-
-
New York
-
Albany, New York, Forenede Stater, 12211
- Rekruttering
- Capital Cardiology Associates
-
Kontakt:
- Rizwan Alimohammad, MD
-
Ledende efterforsker:
- Rizwan Alimohammad, MD
-
Flushing, New York, Forenede Stater, 11355
- Rekruttering
- New York Hospital Queens
-
Kontakt:
- Seth Goldbarg, Dr.
-
Ledende efterforsker:
- Seth Goldbarg, Dr.
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Weill Cornell Medical University
-
Kontakt:
- Jim Cheung, Dr.
-
Ledende efterforsker:
- Jim Cheung, Dr.
-
New York, New York, Forenede Stater, 14621
- Rekruttering
- Rochester General Hospital
-
Kontakt:
- Dmitry Chuprun, MD
-
Ledende efterforsker:
- Dmitry Chuprun, MD
-
Syracuse, New York, Forenede Stater, 13057
- Rekruttering
- SUNY-Upstate Medical University
-
Kontakt:
- Jorge Romero, MD
-
Ledende efterforsker:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Rekruttering
- Sanger Heart and Vascular Institute
-
Kontakt:
- Navid Nafissi, MD
-
Ledende efterforsker:
- Navid Nafissi, MD
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Medical Center
-
Kontakt:
- Daniel Friedman, MD
-
Ledende efterforsker:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43219
- Rekruttering
- Mount Carmel Health System
-
Kontakt:
- Kamel Addo, MD
-
Ledende efterforsker:
- Kamel Addo, MD
-
Columbus, Ohio, Forenede Stater, 43214
- Rekruttering
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
Kontakt:
- Anish Amin, MD
-
Ledende efterforsker:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Penn Presbyterian Medical Center
-
Kontakt:
- John Bullinga, MD
-
Ledende efterforsker:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18702
- Rekruttering
- Geisinger Wyoming Valley
-
Ledende efterforsker:
- Pugazhendhi Vijayaraman, MD
-
Kontakt:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57108
- Rekruttering
- Avera Heart Hospital of South Dakota
-
Kontakt:
- Christopher Stanton, Dr.
-
Ledende efterforsker:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37205
- Rekruttering
- St.Thomas Health
-
Kontakt:
- Ricardo Lugo, MD
-
Ledende efterforsker:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, Forenede Stater, 75093
- Rekruttering
- Heart Hospital Baylor Plano
-
Kontakt:
- Mustafa Dohadwala, MD
-
Ledende efterforsker:
- Mustafa Dohadwala, MD
-
Tyler, Texas, Forenede Stater, 75701
- Rekruttering
- Christus Trinity Mother Frances Health System
-
Kontakt:
- Stanislov Weiner, Dr.
-
Ledende efterforsker:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia Medical Center
-
Ledende efterforsker:
- Pamela Mason, MD
-
Kontakt:
- Pamela Mason, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
Eksperimentel: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
Tidsramme: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Win ratio composite assessment
Tidsramme: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
Tidsramme: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- C2403
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .